Semaglyn Injection Explained: India's New GLP-1 with a Reusable Adjustable Pen
Semaglyn is Zydus Lifesciences' generic semaglutide injection for type 2 diabetes and weight loss in India. The key innovation is a single reusable pen that covers all dose strengths.
If your doctor has recently prescribed Semaglyn, you may be wondering how this injection works and whether it is right for you. That is completely normal. New medicines can feel confusing at first, especially injections. But Semaglyn is simpler to use than most people expect.
This guide explains what it is, how it works, and what to expect - in plain, everyday language.
What is Semaglyn?
Semaglyn is a brand name for semaglutide, a medicine belonging to the class called GLP-1 receptor agonists. It is developed by Zydus Lifesciences, one of India's leading pharmaceutical companies, and co-marketed with Lupin. It is approved by India's drug authority, the DCGI, for two conditions:
- Type 2 Diabetes - improving blood sugar control
- Chronic weight management - for adults with obesity or overweight with related health conditions
GLP-1 is a hormone your gut naturally releases after you eat. It signals your brain that you are full, slows digestion, and helps your body release the right amount of insulin at the right time.
Semaglyn mimics this natural hormone, but with a much longer-lasting effect. This means you feel less hungry, eat less, and your blood sugar stays more stable.
Zydus also markets semaglutide under two other brand names - MASHEMA and ALTERME. Lupin co-markets the same medicine under the names Semanext and Livarise. All use the same molecule, the same clinical evidence, and the same reusable pen device.
The Semaglyn Reusable Adjustable Pen: The Key Differentiator
The most important thing to know about Semaglyn is its delivery device. Most semaglutide injections - including Ozempic and Wegovy - come as separate prefilled pens for each dose strength. As your dose increases, you need a new pen each time.
Semaglyn changes this completely.
The Semaglyn pen is a single reusable adjustable device:
- One pen covers all dose strengths (0.25 mg to 2.4 mg)
- You do not switch pens when your dose increases
- Your doctor adjusts the dose using the same device
- Zydus holds exclusive rights to this pen technology in India
This design reduces cost, eliminates confusion, and makes the entire treatment experience significantly simpler - especially for patients who need the therapy for months or years.
As Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, has stated: "Keeping patient convenience at the core, the innovative pen device is designed to make therapy simpler and improve quality of life."
How Semaglyn is Taken
Semaglyn is given as a subcutaneous injection - just under the skin - once a week, on the same day each week. Common injection sites are the stomach, the upper thigh, or the upper arm.
Your doctor will start you on a low dose and slowly increase it over several weeks. This gradual escalation helps your body adjust and reduces the chance of side effects.
Never change your dose on your own.
How Semaglyn Compares to Ozempic and Wegovy
| Feature | Semaglyn (Zydus) | Ozempic / Wegovy (Novo Nordisk) |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Origin | Developed in India by Zydus | Denmark |
| Pen device | Single reusable adjustable pen | Separate prefilled pen per dose |
| Dose flexibility | Multiple strengths, one pen | Different pen for each dose |
| Expected cost | More affordable (generic + India-made) | Higher, often imported |
| Availability | India-first post patent expiry | Limited access in India |
| Co-marketing | Lupin partnership for wider reach | Novo Nordisk distribution only |
The single adjustable pen is not just a convenience feature. According to reporting on the Zydus-Lupin partnership, this design is expected to lower treatment costs by allowing patients to use multiple doses from one device - a meaningful financial advantage for long-term therapy.
What Results Can You Expect and When?
Results vary between individuals and take time. Here is a realistic timeline:
Weeks 1–4: Appetite begins to reduce. You may feel full faster than usual. Blood sugar can start improving even at the starting dose.
Month 2–3: As the dose increases, hunger reduces more noticeably. Many people start losing weight consistently. Blood sugar often improves meaningfully.
Month 4–6: Typically the period of biggest changes. Studies on semaglutide at higher doses show substantial weight loss and strong blood sugar control.
Beyond 6 months: Continued improvement with sustained lifestyle changes. Regular check-ins with your doctor help fine-tune the dose and diet plan.
Beyond weight and blood sugar, semaglutide has also been shown to benefit blood pressure, cholesterol, and cardiovascular health.
Common Side Effects
Like all medicines, Semaglyn can cause side effects. Most are mild and improve within the first few weeks.
- Nausea - the most common; usually improves after 2–4 weeks. Eating smaller meals helps.
- Vomiting - less common, usually brief
- Reduced appetite - the intended effect, which some find takes adjustment
- Loose stools or constipation - common in the early weeks
- Stomach discomfort or bloating - linked to slower gastric emptying
- Mild fatigue or headache - occasionally reported, usually in the first weeks
Serious side effects are rare. They include pancreatitis and, in people with diabetes, possible changes in vision. Contact your doctor immediately if anything feels severe.
Who Should Not Take Semaglyn?
Semaglyn is not suitable for everyone. Your doctor will screen you carefully. Avoid or use with caution if:
- Pregnant or breastfeeding - not recommended; inform your doctor if you are planning pregnancy
- History of medullary thyroid carcinoma (MTC) or MEN2 syndrome
- Past or current pancreatitis
- Severe kidney or liver disease
- Type 1 Diabetes - not approved for this
- Under 18 years of age - approved for adults only
Always give your doctor a full picture of your medical history, including all other medicines you take.
Why Semaglyn Matters for India
India is facing a serious and growing health challenge. According to the International Diabetes Federation, around 8.9 crore adults in India are living with diabetes. Obesity among Indian women has risen by 91% and among men by 146% over the past two decades.
GLP-1 therapies like semaglutide have already transformed diabetes and obesity treatment globally. But until recently, they were largely inaccessible to Indian patients because of cost and limited availability.
The Zydus-Lupin collaboration directly addresses this gap - combining Zydus' development capabilities with Lupin's network of over 10,000 doctors across India. India-made generic semaglutide, backed by Indian clinical data, distributed through one of the country's widest pharmaceutical networks, is a meaningful step toward making this treatment accessible where it is needed most.
Tracking Your Progress on Semaglyn
Managing weight or blood sugar is a long-term effort. Keeping a consistent weekly log of your weight, fasting sugar, injection day, and symptoms helps your doctor make better decisions at each visit.
WeightEasy supports semaglutide tracking for Indian users - log your dose, weekly weight, side effects, and meal patterns in one place to get the clearest picture of how your treatment is working.
Final Takeaway
Semaglyn is Zydus Lifesciences' generic semaglutide - approved in India for type 2 diabetes and weight management. Its standout feature is a single reusable adjustable pen that covers all dose strengths, making it simpler and more cost-effective than other semaglutide options. Results take time but are meaningful when combined with diet and exercise.
Consult your healthcare provider before starting any medication.
Sources
- Lupin Limited. Lupin and Zydus Sign Licensing Agreement for Co-marketing Innovative Semaglutide Injection in India. March 2026. Lupin Press Release
- Business Standard. Lupin, Zydus partner to co-market semaglutide injection in India. March 2026
- International Diabetes Federation. IDF Diabetes Atlas, 10th Edition. 2021. idf.org
- Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nature Reviews Drug Discovery. 2025
- ICMR-INDIAB-17. Metabolic non-communicable disease health report of India. Lancet Diabetes Endocrinol. 2023
FAQ
What is Semaglyn?
Semaglyn is a generic semaglutide injection developed by Zydus Lifesciences and co-marketed with Lupin in India. It is approved by the DCGI for type 2 diabetes and chronic weight management. Its key feature is a single reusable adjustable pen that covers multiple dose strengths.
How is Semaglyn different from Ozempic?
Both contain semaglutide - the same active molecule. Semaglyn is developed in India by Zydus, making it significantly more affordable. Its standout feature is the reusable pen: a single device covers all dose strengths, unlike Ozempic/Wegovy which require separate prefilled pens at each dose level.
How does the Semaglyn reusable pen work?
The Semaglyn pen is an adjustable multi-dose device that covers all dose strengths (0.25 mg to 2.4 mg) in one reusable pen. As your doctor increases your dose, you use the same pen - no switching required. Zydus holds exclusive rights to this pen technology in India.
What are Semaglyn's side effects?
The most common side effects are nausea, vomiting, diarrhoea, constipation, and reduced appetite - consistent with the GLP-1 class. These are usually mild and improve within the first few weeks. Serious side effects like pancreatitis are rare.
Is Semaglyn affordable in India?
Yes. As a generic semaglutide made in India, Semaglyn is expected to be significantly cheaper than imported Ozempic or Wegovy. The reusable pen further lowers overall cost by eliminating the need for multiple pens as your dose changes.